

Lipopolysaccharide (LPS), which consists of a lipid A anchor, a core oligosaccharide, and a highly variable O-antigen, plays an important role in maintaining membrane integrity and preventing harmful extracellular molecules from penetrating the membrane of Gram-negative bacteria. Although the roles of lipid A and O-antigen have been extensively studied, the role of the core oligosaccharide in envelope stress responses and antibiotic resistance remains relatively poorly understood. In this study, we analyzed the roles of ten enzymes involved in core biosynthesis and modification in envelope stress responses and antibiotic resistance. Our systematic analyses demonstrated that biosynthesis and modification of heptoses present in the inner core of LPS are important for resistance to bile salts and antibiotics. Notably, we found that phosphorylation of the first heptose in the inner core had a role distinct from that of phosphorylation of the second heptose. Defects in heptose biosynthesis resulted in increased membrane permeability. Finally, we found that SpeA/SpeB-dependent putrescine biosynthesis may be partially associated with the sensitivity of the heptose biosynthesis-defective mutant to clindamycin and erythromycin. Taken together, our results demonstrate that the biosynthesis and modification of heptoses in the inner core of LPS are strongly associated with the envelope stress response and antibiotic resistance.
Antibiotic resistance poses a serious challenge to public health worldwide; however, the development of new antibiotic classes for combating bacterial infections, especially those caused by Gram-negative pathogens, has slowed in recent years. Dual-acting hybrid antibiotics with a metabolically non-cleavable covalent bond represent an emerging strategy for developing novel antibiotic classes to overcome antibiotic resistance. The covalent connection between two antibiotics results in a fixed pharmacokinetic profile of a single molecule and can impede bacterial efflux. However, as most antibiotics do not have membrane-destabilizing activity, the resulting increase in molecular weight by connection of two antibiotics could limit their activity against Gram-negative bacteria, whose outer membrane forms a strong barrier blocking the penetration of high-molecular weight antibiotics. Here, we review recent developments in dual-acting hybrid antibiotics targeting Gram-negative bacteria, with a focus on their antibacterial efficacy. We also discuss combination therapy strategies in which the underlying molecular mechanisms of synergy have been characterized. Finally, we outline future directions for the rational design of hybrid antibiotics against Gram-negative pathogens.
Citations